luliconazole

Luliconazole is a potent imidazole antifungal agent characterized by its unique structure containing a dithiolane ring. It exerts its antifungal activity by selectively inhibiting the enzyme lanosterol 14-alpha-demethylase (CYP51), which is responsible for the conversion of lanosterol to ergosterol. The resulting depletion of ergosterol and accumulation of methylated sterol precursors lead to significant alterations in the fungal cell membrane's structure and function, ultimately causing cell death. Developed by Nihon Nohyaku, luliconazole is primarily indicated for the topical treatment of superficial fungal infections, including interdigital tinea pedis, tinea cruris, and tinea corporis caused by organisms such as Trichophyton rubrum and Epidermophyton floccosum. It is noted for its high affinity for the stratum corneum and rapid fungicidal activity.

Brand names

LuzuLuliconLulifin

Other names

(R)-(-)-Luliconazole